Ventripoint Diagnostics turns the ultrasound machine already sitting in every cardiology department into a tool that produces 3D volumetric measurements of all four heart chambers with accuracy comparable to a cardiac MRI — at a fraction of the cost, and without the multi-day wait.
| Ticker | Price | Market Cap | 52w Range | 12-mo Δ | Focus |
|---|---|---|---|---|---|
| TSXV: VPTVentripoint Diagnostics | $0.115 | $21.5M | $0.075 – $0.30 | +55.4% | AI cardiac imaging · MRI-grade from 2D echo |
| NASDAQ: BFLYButterfly Network | $3.42 | $769M | $2.18 – $5.40 | +18.2% | Handheld ultrasound · AI-guided imaging |
| NASDAQ: IRTCiRhythm Technologies | $108.40 | $3.5B | $82 – $130 | +12.6% | Cardiac monitoring · ML-based arrhythmia detection |
| NASDAQ: GEHCGE HealthCare | $78.15 | $35.6B | $71 – $96 | −3.4% | Medical imaging incumbent · MRI/CT/US |
| NYSE: MDTMedtronic | $92.50 | $118.5B | $77 – $96 | +8.1% | Diversified cardiac devices · structural heart |
| NASDAQ: ISRGIntuitive Surgical | $548.20 | $194B | $382 – $617 | +24.7% | Robotic surgery · AI-assisted clinical workflows |
Cardiac MRI is the clinical reference standard for measuring heart function. It is also expensive, slow, and operationally hostile to high-volume cardiology programs. Ventripoint's VMS+™ targets the gap between what doctors need and what their patients can actually access.
VMS+ doesn't compete with MRI by adding hardware. It leverages a proprietary cardiac geometry database — built over more than a decade of clinical research — to reconstruct what a perfect 3D scan would have shown.
Based on the per-scan bed-day savings model Ventripoint developed with Summit Sciences. Estimates only — actual savings vary by institution.
*$40,000 maximum references the high end of bed-day savings cited in management commentary based on the February 26, 2026 CEO.CA "Inside the Boardroom" interview. ROI outputs are estimates for illustrative purposes only.
Enter your email below to start receiving Ventripoint news the moment it hits the wire.
The feed below pulls Ventripoint news releases directly from GlobeNewswire and TheNewswire. Subscribe to the alert list above to get the same updates by email and SMS.
Schedule a walkthrough for your cardiology or echo lab team. A Ventripoint representative will reach out within one business day.
The U.S. cardiovascular devices market is projected to nearly double by 2032, and 75% of U.S. health systems are now rolling out AI-powered clinical tools. Ventripoint sits at the convergence.
Source: Industry market forecasts referenced in Equity Insider news commentary, April 2026.
Healthcare AI is moving out of the pilot phase. Nearly 40% of U.S. hospitals are operating at negative margins, and CFOs are rejecting clinical moonshots in favour of tools with clear ROI. VMS+ pitches as a "bolt-on" — no new capital equipment, no workflow rebuild, immediate impact on bed-day economics.
VMS+ has been cited in approximately 60 peer-reviewed publications and is referenced in clinical research at Guy's and St Thomas' (London), DHZC Berlin, and other major centres. In April 2026, VMS+ 4.0 won a Gold Edison Award — joining peers like Abbott, Medtronic, Heartflow, Viz.ai, and Boston Scientific.
In late 2025 Ventripoint announced a strategic pivot to a Device-as-a-Service subscription model — designed to shorten enterprise sales cycles, build recurring revenue, and lower the upfront barrier for hospitals. New CFO David Swetlow was appointed in December 2025 to execute the refreshed commercial strategy.
Recognized in the Precision Health Technologies sub-category for technical excellence, market readiness, and potential for sustained real-world impact in cardiac care.
VMS+ is in active clinical use at major hospitals in Europe, the U.K., the U.S., and Canada. Recent agreements show the breadth of the addressable market.
Health Division of the Montecristo Group is rolling out VMS+ across Costa Rica's public and private hospital networks, with focus on remote screening for congenital and structural heart disease.
MOU and consulting agreement to support commercialization across Sacramento and San Francisco health systems, including a demonstration deployment and revenue share on 3D echo processing.
Validation study at St. Paul's Hospital in Vancouver — one of Western Canada's leading cardiac programs — evaluating VMS+ as a tool to reduce demand for cardiac MRI scans.
First remote site in a new hub-and-spoke care model delivering AI-enhanced cardiac imaging to remote and Indigenous communities across British Columbia.
Clinical use at the Clinic for Congenital Heart Disease — assessing complex congenital malformations and adjusting therapy based on VMS+ functional measurements.
Multi-year study on adult congenital heart disease patients presented at BSE 2025 showed accuracy comparable to cardiac MRI for right ventricular measurement.
Leading Ventripoint through a refreshed commercial strategy focused on enterprise hospital deployments, the Device-as-a-Service model, and international expansion.
Appointed CFO in December 2025 to scale the VMS+ cardiac imaging platform globally and execute the company's refreshed commercial strategy designed to drive recurring revenue growth.
Industry veteran trained in sonography with sales and marketing leadership at Siemens, Toshiba (Canon), GE, and Intelligent Ultrasound. Driving the congenital heart disease program.
Leading development of a customer ROI model for VMS+ implementation, building a pilot framework that quantifies system impact on outcomes and bed-day savings.
The clinical area Ventripoint was founded on. Strong validation for right ventricle measurement in paediatric and adult CHD patients.
Precise volumetric measurement and ejection fraction tracking for heart failure patients managed across long therapeutic timelines.
Functional cardiac assessment for patients recovering from cardiac surgery — without the operational friction of repeated MRI scheduling.
Monitoring chemotherapy-related cardiac complications in cancer patients — a fast-growing indication as oncology survival rates extend.
Right ventricular function is critical for pulmonary hypertension management — VMS+ delivers the measurement the difficult chamber requires.
Volumetric and functional assessment for patients with valvular heart disease — supporting surgical planning and long-term monitoring.
VMS+ not only gives us a very precise spatial view of complex congenital malformations at any time, but it also provides us with important data on the function of the heart muscle. This allows us to plan therapy even more precisely, check it at any time and adjust it if necessary.
We want to introduce Ventripoint to all our hospital partners, to make it a standard of care.
Having had experience with the older Ventripoint system, the new VMS+ system with its increased functionality is a great addition to our echo lab.
Our aim is that by working together, we can ultimately provide reliable and effective tools for clinicians on a global scale.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca Media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-own Baystreet.ca Media Corp. (BAY). There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision.
The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd. and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful — investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Forward-looking statements contained herein reflect Ventripoint Diagnostics Ltd.'s expectations as of the date of publication and are subject to risks and uncertainties. Actual results may differ materially. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this content.
*The $40,000 per-scan savings figure refers to avoided bed-day costs when cardiac MRIs are replaced or accelerated by the VMS+ workflow, as reported in management commentary and the February 26, 2026 CEO.CA "Inside the Boardroom" interview. Actual savings will vary by institution. ROI calculator outputs are estimates for illustrative purposes only.
Stock prices and quotes displayed on this page are for illustrative purposes only and may not reflect real-time market data. For live trading data, consult your broker or official exchange sources (TSX Venture Exchange, OTC Markets).